Gilead director granted stock options and RSUs

Gilead Sciences director Kelly A. Kramer received new equity awards as compensation.

Rhea-AI Filing Summary

Gilead Sciences director Kelly A. Kramer received new equity awards as compensation. On April 30, 2026, Kramer was granted a non-qualified stock option covering 4,884 shares of Gilead common stock at an exercise price of $130.84 per share, expiring in 2036, with all shares vesting immediately on the grant date.

On the same date, Kramer also received 1,146 restricted stock units, each representing the right to receive one share of Gilead common stock. These RSUs vested 100% immediately at grant. Following the RSU award, Kramer’s reported RSU holdings totaled 20,256 units. These are awards from the company, not open‑market purchases.

Insider Trade Summary

Grant/Award: 6,030 shares

Grant/Award 2 txns

Insider Kramer Kelly A.

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Restricted Stock Unit	1,146	$0.00	$0.00
Grant/Award	Non-qualified Stock Option (Right to Buy)	4,884	$0.00	$0.00

Holdings After Transaction: Restricted Stock Unit — 20,256 contracts (Direct); Non-qualified Stock Option (Right to Buy) — 4,884 contracts (Direct)

Footnotes (3)

1. F1. Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.
2. F2. 100% of the restricted stock units vested immediately upon the grant date of April 30, 2026.
3. F3. 100% of the shares subject to the stock option vested immediately upon the grant date of April 30, 2026.

Key Figures

Stock options granted: 4,884 options Option exercise price: $130.84 per share Option expiration: April 30, 2036 +4 more

7 metrics

Stock options granted 4,884 options Non-qualified stock option grant on April 30, 2026

Option exercise price $130.84 per share Exercise price for 4,884 non-qualified stock options

Option expiration April 30, 2036 Expiration date of newly granted stock options

RSUs granted 1,146 units Restricted Stock Unit award on April 30, 2026

RSUs outstanding after grant 20,256 units Total reported RSU balance following the transaction

RSU vesting 100% at grant All RSUs vested immediately on April 30, 2026

Option vesting 100% at grant All option shares vested immediately on April 30, 2026

Key Terms

Non-qualified Stock Option, Restricted Stock Unit, contingent right, vested immediately, +1 more

5 terms

Non-qualified Stock Option financial

"Non-qualified Stock Option (Right to Buy)"

A non-qualified stock option (NSO) is a contract that lets an employee or service provider buy company shares at a fixed price for a set period, like a voucher to purchase stock later at today’s price. It matters to investors because exercising NSOs creates ordinary income for the holder and can increase share count, affecting a company’s earnings and ownership mix; think of it as a future sale that can dilute existing shareholders and has immediate tax consequences for the recipient.

Restricted Stock Unit financial

"Restricted Stock Unit represents the contingent right to receive one share"

A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.

contingent right financial

"represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock"

vested immediately financial

"100% of the restricted stock units vested immediately upon the grant date"

exercise price financial

"conversion_or_exercise_price: 130.8400"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What equity awards did GILD director Kelly A. Kramer receive?

Kelly A. Kramer received a grant of 4,884 non-qualified stock options and 1,146 restricted stock units. Both awards relate to Gilead Sciences common stock and were issued as compensation rather than open-market purchases or sales.

What is the exercise price and term of Kelly Kramer’s new GILD stock options?

Kramer’s non-qualified stock options have an exercise price of $130.84 per share and expire on April 30, 2036. These options give the right to buy Gilead Sciences (GILD) common stock at that fixed price until expiration.

How do the new restricted stock units for GILD’s Kelly Kramer work?

Each restricted stock unit represents the right to receive one share of Gilead Sciences common stock. Kramer received 1,146 RSUs that vested immediately, turning into an equivalent number of common shares deliverable under the company’s equity compensation terms.

Did Kelly Kramer’s GILD equity awards vest immediately?

Yes. Both awards vested 100% on April 30, 2026. The 1,146 restricted stock units and all 4,884 option shares became fully vested at grant, meaning no further service or performance conditions are required for vesting.

How many GILD restricted stock units does Kelly Kramer hold after this grant?

After the April 30, 2026 grant, Kramer’s reported restricted stock unit balance totaled 20,256 units. Each unit is tied to one share of Gilead Sciences common stock, reflecting his accumulated RSU-based equity compensation position.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/04/2026 - 04:19 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kramer Kelly A.

(Last) (First) (Middle)

333 LAKESIDE DRIVE

(Street)

FOSTER CITY CALIFORNIA 94404

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
GILEAD SCIENCES, INC. [ GILD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/30/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Unit	(1)	04/30/2026		A		1,146		(2)	(2)	Common Stock	1,146	$0	20,256	D
Non-qualified Stock Option (Right to Buy)	$130.84	04/30/2026		A		4,884		(3)	04/30/2036	Common Stock	4,884	$0	4,884	D

Explanation of Responses:

1. Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

2. 100% of the restricted stock units vested immediately upon the grant date of April 30, 2026.

3. 100% of the shares subject to the stock option vested immediately upon the grant date of April 30, 2026.

Remarks:

	/s/ Amy Kim by Power of Attorney for Kelly A. Kramer	05/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)